Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price gapped up before the market opened on Tuesday . The stock had previously closed at $12.10, but opened at $12.70. Mesoblast shares last traded at $12.57, with a volume of 24,916 shares changing hands.
Analyst Upgrades and Downgrades
Several research analysts have commented on MESO shares. StockNews.com cut shares of Mesoblast from a "hold" rating to a "sell" rating in a report on Wednesday, September 4th. Jefferies Financial Group raised Mesoblast from a "hold" rating to a "buy" rating in a research report on Thursday, August 29th. Maxim Group raised Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 price target for the company in a report on Tuesday, September 24th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Mesoblast in a report on Thursday, August 29th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Mesoblast presently has a consensus rating of "Moderate Buy" and an average target price of $11.50.
Read Our Latest Research Report on MESO
Mesoblast Trading Up 3.4 %
The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The company's fifty day moving average price is $10.12 and its two-hundred day moving average price is $8.11.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of MESO. Signaturefd LLC increased its position in Mesoblast by 128.7% in the third quarter. Signaturefd LLC now owns 5,506 shares of the company's stock worth $45,000 after buying an additional 3,099 shares during the period. Perkins Coie Trust Co raised its position in Mesoblast by 15.0% during the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company's stock valued at $94,000 after acquiring an additional 1,500 shares in the last quarter. Pine Valley Investments Ltd Liability Co acquired a new position in shares of Mesoblast during the 2nd quarter valued at about $80,000. Rathbones Group PLC bought a new position in shares of Mesoblast in the second quarter worth about $95,000. Finally, XTX Topco Ltd acquired a new position in shares of Mesoblast during the second quarter valued at about $103,000. Institutional investors and hedge funds own 1.43% of the company's stock.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
See Also
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
